Annual CFI
$27.69 M
+$183.65 M+117.76%
31 December 2023
Summary:
Verve Therapeutics annual cash flow from investing activities is currently $27.69 million, with the most recent change of +$183.65 million (+117.76%) on 31 December 2023. During the last 3 years, it has risen by +$78.82 million (+154.16%). VERV annual CFI is now at all-time high.VERV Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$56.81 M
+$26.66 M+88.43%
30 September 2024
Summary:
Verve Therapeutics quarterly cash flow from investing activities is currently $56.81 million, with the most recent change of +$26.66 million (+88.43%) on 30 September 2024. Over the past year, it has increased by +$68.65 million (+580.07%). VERV quarterly CFI is now -5.46% below its all-time high of $60.09 million, reached on 31 March 2022.VERV Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
$36.44 M
+$68.65 M+213.13%
30 September 2024
Summary:
Verve Therapeutics TTM cash flow from investing activities is currently $36.44 million, with the most recent change of +$68.65 million (+213.13%) on 30 September 2024. Over the past year, it has increased by +$168.17 million (+127.66%). VERV TTM CFI is now -7.45% below its all-time high of $39.37 million, reached on 30 June 2021.VERV TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VERV Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +117.8% | +580.1% | +127.7% |
| 3 y3 years | +154.2% | +126.8% | +121.4% |
| 5 y5 years | - | - | - |
VERV Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +111.6% | -5.5% | +126.8% | at high | +115.2% |
| 5 y | 5 years | at high | +111.6% | -5.5% | +126.8% | -7.5% | +115.2% |
| alltime | all time | at high | +111.6% | -5.5% | +126.8% | -7.5% | +115.2% |
Verve Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $56.81 M(+88.4%) | $36.44 M(-213.1%) |
| June 2024 | - | $30.15 M(-172.4%) | -$32.21 M(+9.8%) |
| Mar 2024 | - | -$41.63 M(+368.1%) | -$29.33 M(-205.9%) |
| Dec 2023 | $27.69 M(-117.8%) | -$8.89 M(-24.9%) | $27.69 M(-121.0%) |
| Sept 2023 | - | -$11.83 M(-135.8%) | -$131.73 M(-24.9%) |
| June 2023 | - | $33.02 M(+114.6%) | -$175.41 M(-12.6%) |
| Mar 2023 | - | $15.39 M(-109.1%) | -$200.66 M(+28.7%) |
| Dec 2022 | -$155.96 M | -$168.31 M(+203.2%) | -$155.96 M(+249.5%) |
| Sept 2022 | - | -$55.52 M(-813.4%) | -$44.63 M(-77.8%) |
| June 2022 | - | $7.78 M(-87.0%) | -$201.43 M(+5.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $60.09 M(-205.5%) | -$190.72 M(-20.2%) |
| Dec 2021 | -$239.10 M(+367.7%) | -$56.98 M(-73.2%) | -$239.10 M(+40.5%) |
| Sept 2021 | - | -$212.32 M(-1248.3%) | -$170.23 M(-532.4%) |
| June 2021 | - | $18.49 M(+57.8%) | $39.37 M(-181.9%) |
| Mar 2021 | - | $11.71 M(-1.5%) | -$48.05 M(-6.0%) |
| Dec 2020 | -$51.13 M(+300.7%) | - | - |
| Dec 2020 | - | $11.89 M(-537.3%) | -$51.13 M(-18.9%) |
| Sept 2020 | - | -$2.72 M(-96.1%) | -$63.01 M(+4.5%) |
| June 2020 | - | -$68.94 M(-898.0%) | -$60.30 M(-798.0%) |
| Mar 2020 | - | $8.64 M | $8.64 M |
| Dec 2019 | -$12.76 M | - | - |
FAQ
- What is Verve Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Verve Therapeutics?
- What is Verve Therapeutics annual CFI year-on-year change?
- What is Verve Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Verve Therapeutics?
- What is Verve Therapeutics quarterly CFI year-on-year change?
- What is Verve Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Verve Therapeutics?
- What is Verve Therapeutics TTM CFI year-on-year change?
What is Verve Therapeutics annual cash flow from investing activities?
The current annual CFI of VERV is $27.69 M
What is the all time high annual CFI for Verve Therapeutics?
Verve Therapeutics all-time high annual cash flow from investing activities is $27.69 M
What is Verve Therapeutics annual CFI year-on-year change?
Over the past year, VERV annual cash flow from investing activities has changed by +$183.65 M (+117.76%)
What is Verve Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of VERV is $56.81 M
What is the all time high quarterly CFI for Verve Therapeutics?
Verve Therapeutics all-time high quarterly cash flow from investing activities is $60.09 M
What is Verve Therapeutics quarterly CFI year-on-year change?
Over the past year, VERV quarterly cash flow from investing activities has changed by +$68.65 M (+580.07%)
What is Verve Therapeutics TTM cash flow from investing activities?
The current TTM CFI of VERV is $36.44 M
What is the all time high TTM CFI for Verve Therapeutics?
Verve Therapeutics all-time high TTM cash flow from investing activities is $39.37 M
What is Verve Therapeutics TTM CFI year-on-year change?
Over the past year, VERV TTM cash flow from investing activities has changed by +$168.17 M (+127.66%)